Sign in
CompletedNo phase

The SUN Clinical Trial (Safety Utilizing NUsurface Meniscus Implant)

Key facts

Who runs it
Phoenix Kinetics
Where
Arlington, Baton Rouge, Boulder, Denver, Greenwood, La Mesa, Long Beach, New Orleans, Phoenix, Portland, Richmond, Salt Lake City, and San Francisco, United StatesSee the 13 sites
Trial code
Status
Completed
People taking part
115 people enrolled
Started
Dec 2015
Ended
29 May 2024
Type of study
Interventional
Treatments tested
  • NUsurface® Meniscus Implant
Record updated
31 August 2026

Who can take part

Age
30 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 45 criteriaShow less

Who can take part

  • Had > 6 months ago a medial partial meniscectomy as confirmed by patient history and MRI
  • Has a KOOS Pain of ≤ 75 (100 being the highest attainable and no pain)
  • Is between age 30 and 75 years (inclusive) at the time of study treatment
  • Has neutral alignment ±5º of the mechanical axis, as measured from the angle formed by a line drawn from the center of the femoral head to the medial tibial spine and a line drawn from the medial tibial spine and the center of the ankle joint
  • Has ≥ 2 mm intact medial meniscal rim capable of being fitted with a NUsurface® device
  • Is able to do the study required follow-up visits, questionnaires, X-rays and MRI's
  • Is able to read and understand the English language if treated at a U.S. site or read and understand one of the official country languages if treated at a site Outside the U.S
  • Is able and willing to understand and sign the Informed Consent Form

Who cannot take part

  • Has evidence of a Outerbridge Grade IV cartilage loss on the medial tibial plateau or femoral condyle that potentially could contact a NUsurface implant (e.g., a focal lesion > 0.5 cm2 correlating to a circular defect of > 8 mm in diameter)
  • Had an ACL reconstruction performed < 9 months prior to study treatment
  • Decides to receive (if eligible and an option) allograft medial meniscus transplantation
  • Received any type of prosthetic knee implant made of artificial non-resorbable plastic, metal or ceramic, not including the NUsurface® Meniscus Implant
  • Had a previous medial femoral condyle surgery (not including microfracture) or High Tibial Osteotomy (HTO)
  • Anticipates having another lower extremity surgery during the study period
  • Has received any corticosteroid knee injections ≤ 3 months prior to study treatment
  • Patients who are contraindicated for MRI (i.e., pacemaker, defibrillator, cochlear implants, etc.)
  • Has insufficiency fractures or avascular necrosis of the medial compartment
  • Has an active infection or tumor (local or systemic)
  • Has any type of knee joint inflammatory disease including Sjogren's syndrome
  • Has any medical condition that does not allow possible arthroscopy of the knee
  • Is contraindicated for corticosteroid injections (i.e., patients with allergy to any of the components or with idiopathic thrombocytopenic purpura)
  • Has ipsilateral or contralateral lower limb joint conditions that may affect ambulation or KOOS (e.g. have a leg length discrepancy > 2.5 cm [1 inch], causing a noticeable limp)
  • Is mentally incapacitated (incapable of appraising or controlling conduct) or have mental disability (e.g., dementia or Alzheimer's)
  • Is contraindicated for hyaluronic acid injections (i.e., patients with known hypersensitivity [allergy] to hyaluronan [sodium hyaluoronate] preparations); patients having knee joint infections or skin diseases or infections in the site of possible injections
  • Has a symptomatic knee because of a tear that could be addressed by a repeat partial meniscectomy leaving > 4 mm of medial meniscus rim
  • Has complete disruption of the posterior root attachment of the meniscus
  • Has lateral compartment pain and Grade III or Grade IV Outerbridge cartilage score in the lateral compartment
  • Has a varus or valgus knee deformity > 5º requiring a tibial or femoral osteotomy
  • Has a laxity level of more than Grade II (IKDC), primary or secondary to an injury of the anterior cruciate ligament (ACL) and/or posterior cruciate ligament (PCL) and/or lateral collateral ligament (LCL) and/or medial collateral ligament (MCL)
  • Has significant trochlear dysplasia, patellar instability or symptomatic patellar misalignment
  • Has patellar compartment pain and Grade III or Grade IV Outerbridge cartilage score in the patellar compartment
  • Compared to a normal knee, has obvious radiological evidence of medial femoral squaring, anatomical variance in the medial tibial plateau, or irregularly shaped cartilage surface
  • Has a BMI > 32.5 at the start of study treatment
  • Has a knee flexion contracture > 10º
  • Has flexion < 90º
  • Has neuropathic knee osteoarthropathy, also known as Charcot joint
  • Has neurological deficit (sensory, motor, or reflex)
  • Is currently involved in another investigation of the lower extremity
  • Has chondrocalcinosis
  • Is on immunostimulating or immunosuppressing agents
  • Is a female who is lactating, expecting, or is intending to become pregnant during the study period
  • Is an active smoker
  • Is a prisoner
  • Is a patient who has economic incentive not to improve
  • Certain patient populations that are at high risk for poor healing or outcomes such as patients who have a co-morbidity that reduces life expectancy to less than 36 months

Where in United States

  • Arlington Orthopedic Associates, PAArlington, United States
  • Baton Rouge Orthopaedic ClinicBaton Rouge, United States
  • CU Sports MedicineBoulder, United States
  • Advanced Orthopaedics & Sports Medicine SpecialistsDenver, United States
  • OrthoIndyGreenwood, United States
  • Horizon Clinical ResearchLa Mesa, United States
  • Long Beach Memorial Medical CenterLong Beach, United States
  • Ochsner Sports Medicine InstituteNew Orleans, United States
  • Banner-University Medical Center PhoenixPhoenix, United States
  • Sports Medicine OregonPortland, United States
  • OrthoVirginiaRichmond, United States
  • Comprehensive Orthopaedics & Sports MedicineSalt Lake City, United States
  • St. Mary's Medical CenterSan Francisco, United States

About the trial

What the trial wants to find out

The NUsurface® Meniscus Implant SUN Clinical Trial is a multi-center, single-arm, prospective, open label, non-randomized, observational clinical trial to gather safety and probable clinical benefit data on the NUsurface® Meniscus Implant in treated the target population.

The group in the trial

  • NUsurface Meniscus ImplantTreatment being tested

    All eligible patients will receive the NUsurface® Meniscus Implant.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The SUN Clinical Trial (Safety Utilizing NUsurface Meniscus Implant). A Multi-center, Single-arm, Prospective, Open-label, Non-randomized, Observational Clinical Study
Record updated
31 August 2026